Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gynecologic 1

Conditions

Breast Neoplasms 6Recurrent Uterine Corpus Sarcoma 1Neoplasms 1Neoplasm Metastasis 1Endometrial Adenocarcinoma 1

Interventions

Taxes 5Paclitaxel 5Carboplatin 4Immunoglobulin G 2Disulfides 2Cisplatin 2Bevacizumab 2temsirolimus 1pegfilgrastim 1nintedanib 1ixabepilone 1cediranib 1brivanib 1Sunitinib 1Sirolimus 1Radiotherapy, Intensity-Modulated 1Platinum 1Metformin 1Medroxyprogesterone Acetate 1Medroxyprogesterone 1MK 2206 1Granulocyte Colony-Stimulating Factor 1Gemcitabine 1Filgrastim 1Epothilones 1Doxorubicin 1Brachytherapy 1AZD 6244 1ALK1-Fc fusion protein, human 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Endometrial Adenocarcinoma × Epothilones × Clear all
NCT00977574 2026-05-29

Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer

National Cancer Institute (NCI)

Phase 2 Active not recruiting
349 enrolled 11 charts
GynecologicSarcoma

Endometrial Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡